ISPOR 2024 Home
Toggle navigation
About
News Center
Award Winners
Program
Program
Learning Formats
Plenary Sessions
Posters
Program Committee
Digital Conference Pass
Exhibits & Sponsorship
Sponsor List
Exhibitor Directory
Media Partners
Photo Gallery
ISPOR
2024
May 5-8, 2024
Home
Events
Past Conferences
ISPOR 2024
Program
Plenary Sessions
Session
Economic Evaluation for the United States (US) of the Overall Survival Analysis of Cemiplimab Plus Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer (NSCLC) With at Least 50% PD-L1 Positivity
May 6, 2024, 11:30 AM
«
1721
1722
1723
(current)
1724
1725
1726
1727
1728
1729
1730
»